David A. Siegel Atea Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 577,400 shares of AVIR stock, worth $2.12 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
577,400
Previous 319,100
80.95%
Holding current value
$2.12 Million
Previous $973,000
139.67%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AVIR
# of Institutions
119Shares Held
49.6MCall Options Held
108KPut Options Held
327K-
Black Rock Inc. New York, NY9.24MShares$33.9 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.15MShares$22.6 Million0.71% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.54MShares$20.3 Million14.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$17.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.08MShares$15 Million2.01% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $306M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...